Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for HCV Associated Cryoglobulinemic Vasculitis
NCT00029107Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2001
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in cryoglobulinemic vasculitis, sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2001; status: completed.
02
Drugs
rituximab
03
Conditions
cryoglobulinemic vasculitis
Beyond the preview
Go deeper on NCT00029107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00029107.